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Bristol Myers Squibb Australia, Mulgrave, Victoria, AustraliaA B S T R A C TObjectives: To compare processes and timings of regulatory and
subsidized access systems for medicines across seven jurisdictions
within the Asia-Paciﬁc region. Methods: A questionnaire was devel-
oped focusing on regulatory and health technology assessment–
based subsidized access processes and timings in each of the seven
surveyant’s jurisdictions. Results: Australia and Thailand are the
only two jurisdictions that formally allow the subsidized access
evaluation process to be conducted in parallel with the regulatory
evaluation process. Australian, Japanese, Korean, New Zealand, and
Taiwanese systems afford broad coverage, whereas Chinese and Thai
systems provide limited coverage for medicines under patent. Sub-
sidized access systems for all jurisdictions except Thailand have an
associated patient co-payment for each medicine/prescription. The
biggest disparity across the study group relates to time from regu-
latory submission to subsidized access of patented medicines—ee front matter Copyright & 2015, International S
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ndence to: Greg Cook, Bristol Myers Squibb Austraranging from just over 1 year (Japan) to a minimum of 5 years (China).
Conclusions: There is consistency across the seven jurisdictions
studied in relation to regulatory and subsidized patient access
processes—that is, regulatory approval is required before subsidized
access review; subsidized access coverage is broad; and the cost of
medicine subsidization is offset, in part, by patient co-payments.
Although local differences will always exist in relation to budget and
pricing negotiation, there may be efﬁciencies that can be applied
across systems to improve time to subsidized access. Closer under-
standing of regulatory and subsidized access systems can lead to
best-practice sharing and, ultimately, timely access and better health
outcomes for patients.
Keywords: access, Asia-Paciﬁc, HTA.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In the Asia-Paciﬁc region, most countries provide access to
medicines through government subsidized programs, which
range from national tax-funded schemes such as the Australian
Pharmaceutical Beneﬁts Scheme (PBS) [1] through to coverage of a
speciﬁc population such as the Thailand Social Security Scheme
for private sector workers [2].
Medicines are traditionally assessed by a regulatory agency
such as the New Zealand Medicines and Medical Devices Safety
Authority [3] or the Chinese Food and Drug Administration [4]
before market authorization. The regulatory process includes an
extensive scientiﬁc evaluation of the particular drugs’ beneﬁt/risk
proﬁle and was traditionally the main hurdle before patients
could gain access to new medicines. An example of this was the
negative list system of South Korea pre-2008, in which only those
drugs that were not covered by the Health Insurance Review and
Assessment Service were speciﬁed [5].Although Australia has had a cost-effectiveness–based sub-
sidized access process in place after regulatory approval since
1993, formal subsidized access processes in other Asia-Paciﬁc
jurisdictions are less than a decade old. Navigating these systems
can be as simple as submitting a pricing application, which at the
moment is the norm in Japan [6], or as complex as a full-scale
societal health technology assessment (HTA) as, for instance, in
Taiwan [5]. An unintended consequence of this extra layer of
scrutiny is a possible delay in access to medicines for patients
because manufacturers now have to clear two hurdles (registra-
tion and subsidized access) before they can provide the new
drugs to patients.
The aim of this study was to compare and contrast processes
and timings of regulatory and subsidized access systems for
medicines across the Asia-Paciﬁc region qualitatively. Although
the jurisdictions involved in this study have substantially differ-
ent demographic and economic characteristics, and are in differ-
ent phases of HTA development and utilization [4], learningsociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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will ensure timely access to new medicines in the future.Methods
A total of seven jurisdictions were selected to participate in the
survey (Australia, China, Japan, South Korea, New Zealand,
Taiwan, and Thailand). The seven jurisdictions are linked by
the fact that each uses HTA to assist in decision making speciﬁc
to subsidized patient access of medicines.
A common template requesting information speciﬁc to regu-
latory and subsidized access processes, timelines, level of cover-
age, and patient co-payment details was developed and sent out
to participating jurisdictions (see Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.03.013).
The regulatory process was deﬁned as the assessment of the
risk-beneﬁt proﬁle by the jurisdiction’s regulatory body. The
subsidized access process was deﬁned as the assessment of the
value (cost-effectiveness) of a medicine by the jurisdiction’s HTA
body. The time taken to pass through the regulatory and subsidized
access systems was deﬁned as time from submission through to
registration date and subsidized access date, respectively.
In addition, information speciﬁc to the timelines of registra-
tion and subsidized access to two new medicines (apixaban for
prevention of venous thrombo-embolism (VTE-P) and alogliptin
for type 2 diabetes mellitus [T2DM]) was sourced from each
jurisdiction. These data were captured to examine whether
“real-life” timelines associated with registration and subsidized
access of new medicines matched the theoretical timelines
speciﬁc to each jurisdiction. The two medicines were selected
in an attempt to gain information from as many of the seven
jurisdictions as possible.
Health economics and outcomes research or market access
representatives from Bristol Myers Squibb in individual jurisdic-
tions were asked to complete the questionnaire either from their
own knowledge or with the support of local experts. Data
obtained were synthesized and rechecked by local experts in
HTA to avoid bias or misinterpretations.
The questionnaire included the following items:1. Name of regulatory body and regulatory evaluation
committee.2. Time frame associated with the registration process.
3. Name of subsidized access body and subsidized evaluation
committee.
4. Time frame associated with the subsidized access process.
5. Level of subsidized access coverage.
6. Patient co-payments associated with subsidized access
coverage.
7. Registration and subsidized access timelines speciﬁc to apix-
aban for VTE-P and alogliptin for T2DM.
The responses were reviewed by the authors and synthesized
qualitatively except for time frames, which were directly com-
pared using nonstatistical methods.Results
An outline of each of the regulatory and subsidized access
systems across the seven Asia-Paciﬁc jurisdictions studied is
presented below, followed by a summary comparison.
Australia
Applications for the registration of new medicines and indica-
tions are evaluated by the Australian Therapeutic GoodsAdministration (TGA), with the standard evaluation process set
at 12 months [7]. Before January 1, 2011, a TGA delegate’s positive
recommendation was required before a sponsor could apply for
subsidized access via the PBS; however, as a result of the
Australian government’s memorandum of understanding with
Medicines Australia, submissions to the Pharmaceutical Beneﬁts
Advisory Committee (PBAC) for listing new medicines and indi-
cations on the PBS can occur in parallel with TGA submissions [8].
The PBAC evaluation process is 17 weeks, with a further 20 weeks
built into the system before PBS listing to cover pricing and
administrative requirements. Medicines with a high budget
impact (i.e. 4AU$20 million incremental cost to the PBS) require
Australian government cabinet approval [9] and for these med-
icines PBS listing times may therefore extend beyond the theo-
retical 72 weeks minimum time from regulatory application to
PBS listing (Fig. 1).
The PBS lists medicines available to be dispensed to patients
at a government-subsidized price. The scheme is available to all
Australian residents who hold a current Medicare card as well as
to overseas visitors from countries with which Australia has a
reciprocal health care agreement [10]. A ﬂat-fee patient co-
payment exists within the Australian system, with adults cur-
rently paying AU $37.70 (US $29.39) and concession card holders
AU $6.10 (US $4.76) per prescription (Table 1) [11].
China
The China Food and Drug Administration falls directly under the
State Council of the People’s Republic of China, which is the
authority of drug regulation in mainland China. China Food and
Drug Administration registration of new medicines is required
before selection for inclusion within China’s two major health
insurance programs covered under the Basic Health Insurance
Scheme (BHIS): the urban resident basic medical insurance
scheme and the new rural cooperative medical system [12]. This
medicine selection process for the urban population program
occurs every 2 to 4 years, with revision of the formulary depend-
ent on the Ministry of Labor and Social Security decision that it is
time for a review [13]. Figure 1 illustrates that the theoretical time
from regulatory application to subsidized access in China is
greater than in any of the other jurisdictions studied.
The philosophy of the BHIS formulary is to provide basic drug
coverage within a cost-containment setting. Because the BHIS is
jointly funded by the government, employers, and employees, a
patient co-payment does exist for BHIS-listed medicines, although
the exact amount depends on the subinsurance system (Table 1).
Japan
The Japanese Pharmaceutical and Medical Devices Agency scien-
tiﬁcally reviews new medicines and indications for marketing
authorization [14]. Following Pharmaceutical and Medical Devices
Agency registration, subsidized access covering all Japanese
citizens can be applied for via the National Health Insurance
Scheme [6]. The process for National Health Insurance (NHI)
listing in Japan can be very quick (8–12 weeks), with Figure 1
illustrating that of the seven jurisdictions studied, Japan has the
shortest theoretical time frame from regulatory application to
subsidized access (60 weeks).
Depending on the age and employment status of a patient, co-
payments in Japan range from 0% through to 30% of the cost of
the subsidized medicine (Table 1).
South Korea
Registration of new medicines and indications by the South
Korean Ministry of Food and Drug Safety can take 12 to 18
months depending on whether the medicine is a chemical or
Fig. 1 – Time to progress through regulatory and subsidized patient access systems across Asia-Paciﬁc (Theoretical). CFDA,
China Food and Drug Administration; BHIS, Basic Health Insurance Scheme; FDA, Food and Drug Administration; MFDS,
Ministry of Food and Drug Safety; NHI, National Health Insurance; NLEM, National List of Essential Medicines; PBS,
Pharmaceutical Beneﬁts Scheme; PBAC, Pharmaceutical Beneﬁts Advisory Committee; PHARMAC, Pharmaceutical
Management Agency; PMDA, Pharmaceutical and Medical Devices Agency; TFDA, Taiwanese Food and Drug Administration;
TGA, Therapeutic Goods Administration. *Indicative only as guidelines (not cited in guidelines). †Current process (August
2014); speciﬁc to urban population only.
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apply to the Health Insurance Review and Assessment service for
subsidized market access for their medicines via the South
Korean NHI scheme [15]. Evaluation and time to NHI listing can
take an additional 12 months postregistration, although since
September 2014, the government now allows subsidized access
submissions in South Korea when the review of safety and
efﬁcacy of a new drug is positive and before a ﬁnal regulatory
approval decision.
The South Korean system affords broad coverage to 99% of
South Korean citizens, with patient co-payments being a per-
centage component of the cost of the subsidized medicine— for
example, 5% for oncology medicines, 10% for medicines to treat
rare diseases, and up to 30% for other medicines (Table 1).New Zealand
Medsafe (the New Zealand Medicines and Medical Devices Safety
Authority) is responsible for the regulation of medicines in New
Zealand [16]. As with most of the jurisdictions studied in this
article, registration of new medicines and indications in New
Zealand takes approximately 12 months. Upon registration,
sponsor companies can apply to the Pharmacology andTherapeutics Advisory Committee for subsidized access via the
Pharmaceutical Management Agency (PHARMAC). Although
guidelines do not stipulate a speciﬁc time frame for Pharmacol-
ogy and Therapeutics Advisory Committee evaluation, theoret-
ically PHARMAC listing can take as little as 32 weeks after
Medsafe registration [17].
PHARMAC affords universal coverage of subsidized medicines
for New Zealand residents, with patient co-payments at the
lower end of the seven jurisdictions studies—at a ﬂat fee of NZ
$5 (US $3.76) per prescription and free for patients younger than 6
years (Table 1) [17].Taiwan
New medicines and indications are reviewed and evaluated by
the Taiwanese Food and Drug Administration before granting of
registration in Taiwan. Depending on the complexity of the
application, evaluation and approval can take up to 2 years [18].
Sponsor companies can then submit applications for NHI sub-
sidization. Submissions are evaluated by the Drug Beneﬁt Com-
mittee who makes recommendations to the Bureau of National
Health Insurance [19]. NHI evaluation and listing can take
between 30 weeks and one and a half years.
Table 1 – Comparison of subsidized patient access systems across the Asia-Paciﬁc.
Jurisdiction Subsidized patient access system Coverage Patient co-payment
Australia Pharmaceutical Beneﬁts
Scheme (PBS)
 Universal coverage of subsidized
medicines for Australian residents
 AU $37.70 (US $29.39) (adult)
 AU $6.10 (US $4.76) (concession)
China Basic Health Insurance
Scheme (BHIS)—urban and
rural schemes
 Covering urban and rural residents  Yes (amount depends on the
subinsurance system)
Japan National Health Insurance
(NHI) Scheme
 Coverage to all Japanese citizens  30%
 10% or 20% (elder and
preschool child
South Korea NHI Scheme  Coverage to 99% of Korean citizens  30%
 5% oncology medicines; 10%
rare disease medicines
New Zealand Pharmaceutical Management
Agency (PHARMAC)
 Universal coverage of subsidized
medicines for New Zealand residents
 NZ $5 (US $3.76)
 Free (younger than 6 y of age)
Taiwan National Health Insurance
Administration (NHIA)
 Coverage to 99.9% of Taiwanese citizens  NTD20 (US $0.64) for medicines
o NTD100 (US $3.19)
 Add NTD20 (US $0.64) per
additional NTD100 medication cost
 Cap for co-payment at NTD200
(US $6.37)
Thailand National List of Essential Medicines  Coverage of generics and cost-effective
patented medicines for Thai citizens
 No co-payment
Note. Foreign exchange rates: sourced March 3, 2015.
NTD, New Taiwanese dollar.
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citizens with a scaled patient co-payment in place. Currently, the
patient co-payment is New Taiwanese dollar (NTD) 20 (US $0.64)
for medicines up to NTD100 (US $3.19), with an additional NTD20
required for every additional NTD100. A co-payment cap is set at
NTD200 (US $6.37) (Table 1).
Thailand
Registration of new medicines and indications in Thailand occur
via the Thailand Food and Drug Administration [2]. Evaluation
and registration can take between 1 and 2 years depending on
whether the medicine is a chemical or biological agent. Subsi-
dized access submissions are made to the Health Intervention
and Technology Assessment Program for approval to be placed
on the National List of Essential Medicines [19]. Although this
process can take between 2 and 3 years to complete, it can be
done in parallel with the regulatory process, thereby reducing
overall time to subsidized market access (Fig. 1). The Thailand
subsidized access system covers generic medicines and patented
medicines that have been proven cost-effective for all Thai
citizens and is not associated with a patient co-payment
(Table 1).
Summary
Time to progress through regulatory and subsidized access
systems varies across the seven Asia-Paciﬁc jurisdictions studied
(Fig. 1), with Australia and Thailand the only jurisdictions that
formally allow the subsidized access evaluation process to be
conducted in parallel with the regulatory evaluation process.
Note that a subsidized access submission in Korea can occur 2
months before the ﬁnalization of registration under exceptional
circumstances.
Figure 1 also demonstrates that Japan has the shortest
“theoretical” time from regulatory submission to subsidized
market access for medicines at 60 weeks, followed by Australia
(72 weeks), New Zealand (84 weeks), South Korea (92 weeks),Thailand (104 weeks), Taiwan (110 weeks), and China (up to 5
years). A review of recent examples of medicines passing through
regulatory and subsidized access systems across Asia-Paciﬁc
generally conﬁrmed the order and theoretical timings outlined
in Figure 1.
Table 2 illustrates that with respect to the medicine apixaban
for the prevention of venous thromboembolism, Australia had
the shortest time from registration to subsidized access (21
weeks), followed by Taiwan and South Korea (42 and 60 weeks,
respectively). Note that complete data for China, Japan, New
Zealand, and Thailand were not available. Data sourced speciﬁc
to the medicine alogliptin for the treatment of T2DM demon-
strated that Japan had the shortest time from registration to
subsidized access (9 weeks), followed by Australia and South
Korea (13 and 30 weeks, respectively). Again not all jurisdictions
could provide complete data, with alogliptin not yet subsidized in
China, New Zealand, Taiwan, and Thailand at the time of
research.Discussion
A review of the regulatory and subsidized patient access pro-
cesses across seven Asia-Paciﬁc jurisdictions was conducted in
an effort to not only learn about the nuances of each system but
also look for potential examples of best-practice that could be
considered by individual jurisdictions.
Although regulatory systems in each of the jurisdictions
studied are well established, variation exists with regard to the
extent to which HTA plays a role in the subsidized access
evaluation process. Australia was the ﬁrst country to directly
link HTA economic evaluation to subsidized access to medicines,
with the Australian government from 1993 requiring the PBAC to
consider the cost-effectiveness of all new drugs for which PBS
subsidy was being sought. [20] New Zealand followed soon after,
with HTA evaluation becoming part of the subsidized access
decision-making process relatively recently in South Korea (2006),
Thailand (2007), and Taiwan (2007) [21,22]. Although HTA in
Table 2 – Time to progress through subsidized patient access systems across Asia-Paciﬁc (practical examples:
apixaban for VTE-P and alogliptin for T2DM).
Jurisdiction Date of registration Date of subsidized access Time from registration to access (wk)
Apixaban for VTE-P
Australia July 2011 January 2012 21
Taiwan August 2013 June 2014 42
South Korea November 2011 January 2013 60
New Zealand June 2013 NA 60þ
Thailand November 2012 NA 91þ
Alogliptin for T2DM
Japan April 2010 June 2010 9
Australia September 2013 December 2013 13
South Korea May 2013 January 2014 30
NA, not applicable/available; T2DM, type 2 diabetes mellitus; VTE-P, prevention of venous thromboembolism.
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as ﬁrm a footing as established HTA jurisdictions. Recent com-
mitments from governments, however, may see HTA increase in
importance in these jurisdictions [23].
In general, there is consistency across the seven Asia-Paciﬁc
jurisdictions studied in relation to regulatory and subsidized
patient access processes. Regulatory approval is required before
subsidized access review; subsidized access coverage is broad
within the Australian, Japanese, Korean, New Zealand, and
Taiwanese systems; and the cost of medicine subsidization is
offset, in part, by patient co-payments in all subsidized access
systems except for Thailand.
The biggest disparity across the study group relates to the
time taken from regulatory submission to subsidized access—
with times ranging from just over 1 year to greater than 5 years.
Although local differences will always exist in relation to ﬁnal
budget and pricing negotiation, there may be technical and
administrative efﬁciencies that can be applied across systems
to improve time to subsidized access—a key and growing focus
for patients and advocacy groups.
Clearly, parallel regulatory and subsidized access evaluation is
one area in which time efﬁciencies can be gained. Currently,
Australia, Thailand, and South Korea allow for parallel processing.
In Australia, any risk associated with the regulatory agency not
granting market authorization is offset by 1) the sponsor company
paying a cost-recovery fee to cover resources speciﬁc to the
subsidized access evaluation and 2) agreement that the outcome
of the assessment by the subsidized access agency will not be made
publicly available until the regulatory agency has made a decision.
Another potential way to reduce time to subsidized access is to
consider how to remove duplication from regulatory and subsi-
dized access assessments. A recent collaboration between the
European Medicines Agency and the European network for Health
Technology Assessment was established and is examining ways of
improving the contribution of regulatory assessment reports to the
assessment of medicinal products by HTA bodies [24]. Although the
assessment of relative effectiveness should remain the remit of
subsidized access agencies, there are data and review efﬁciencies
that can be implemented. Recommended outcomes from collabo-
rations such as these could be used globally to improve commu-
nications within sponsor companies, expand dialogue between
regulators and HTA bodies, support policymaker decisions, and
improve time to subsidized access for patients in the future.
A potential limitation of this study relates to the data gaps
seen in the practical examples looking at time to subsidized
access for the two selected medicines (apixaban for VTE-T;
alogliptin for T2DM). Although intended to test the theroretical
time frames to subsidized access across jurisdictions (displayedin Fig. 1), the medicines selected had not been granted subsidized
access in all jurisdictions studied. For the jurisdictions where
data were available, the timing of subsidized access matched the
jurisdiction order in Figure 1. A follow-up review at a later time
point and/or investigation of additional medicines will provide
further clarity.
In conclusion, although regulatory systems are well estab-
lished, formalized subsidized access systems are relatively new,
with HTA processes developing at uneven speeds [25]. Closer
understanding of different regulatory and subsidized access
processes within Asia-Paciﬁc will allow for best-practice cross-
pollination, optimal and timely subsidized access, and, ulti-
mately, better outcomes for patients.Acknowledgments
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